Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 4/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30094802 | 0.92 | GLP1R (0.59) | GLP1RSIRT6SIRT1TLR2CHRNA1 | |
| SCHEMBL29336336 | 0.89 | GLP1R (0.66) | GLP1RNOD1TLR2LPAR3LPAR1 | |
| SCHEMBL18715398 | 0.88 | GLP1R (0.56) | GLP1RSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL29336162 | 0.87 | GLP1R (0.64) | GLP1RNOD1TLR2LPAR3 | |
| SCHEMBL22055442 | 0.85 | GLP1R (0.67) | GLP1RSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL14642472 | 0.85 | GLP1R (0.67) | GLP1RSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL14903000 | 0.84 | GLP1R (0.49) | GLP1RSIRT6SIRT1NOD1TLR2 | |
| SCHEMBL16315782 | 0.84 | GLP1R (0.51) | GLP1RSIRT6SIRT1TLR2CHRNA1 | |
| SCHEMBL16315786 | 0.84 | GLP1R (0.51) | GLP1RSIRT6SIRT1TLR2CHRNA1 | |
| SCHEMBL27142855 | 0.83 | GLP1R (0.52) | GLP1RSIRT6SIRT1TLR2CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | GLP1R 319/4885SIRT6 1687/4885SIRT1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.